INIFY Laboratories AB
The answer first
Does INIFY Laboratories beat the market?
Yes, INIFY Laboratories has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 44% of Nordic stocks
- Quality80
- Value4
- Trend63
No. 73 of 195 in healthcare
Max for seven days
Follow INIFY Laboratories with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about INIFY Laboratories
Your first answer is free, no account needed.
Do you own INIFY Laboratories, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with INIFY Laboratories and a few more. Free, no card.
Super Stock+44.6%In short
- INIFY Laboratories has risen 40.3% over the past year, including dividends.
- Overall, INIFY Laboratories ranks better than 44% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 79.9%. The price is 68.8% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 44% of Nordic stocks.
No. 73 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 52 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity–
- Asset turnoverSales divided by everything the company owns0.15
- Return on equityProfit divided by equity−59.7%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 168 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity4.0
- P/SPrice divided by sales24.3
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flow–
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 60 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−35.7%
- 6 months+36.5%
- 9 months+40.3%
- 12 months+40.3%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About INIFY Laboratories
INIFY Laboratories AB is a company in healthcare, listed on Oslo Børs. The share trades in NOK.
INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.


See the full analysis of INIFY Laboratories.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card